• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sage Therapeutics, Inc. - Common Stock (NQ:SAGE)

8.680 UNCHANGED
Last Price Updated: 4:00 PM EDT, Jul 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sage Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
News headline image
Sage Therapeutics Board of Directors Initiates Review of Strategic Alternatives and Rejects Biogen’s Unsolicited Acquisition Proposal
January 27, 2025
From Sage Therapeutics, Inc.
Via Business Wire
News headline image
Deal Dispatch: Biden Punts TikTok Ban To Trump, Plus Another Legacy Retailer Goes Bankrupt ↗
January 17, 2025
Deal opportunities abound: KKR & Co.'s stake in Maya; DuPont's electronics business; Ingevity's North Charleston site; and S&W Seed Company. 
Via Benzinga
Topics Government
News headline image
Stocks to Watch in 2025: PHIO, LPTH, KAVL, Promising Innovations, Growth Opportunities, Etc. … more inside
January 13, 2025
Via AB Newswire
Topics Regulatory Compliance
News headline image
Where Sage Therapeutics Stands With Analysts ↗
January 02, 2025
 
Via Benzinga
News headline image
Where Sage Therapeutics Stands With Analysts ↗
December 16, 2024
 
Via Benzinga
News headline image
Cracking The Code: Understanding Analyst Reviews For Sage Therapeutics ↗
November 20, 2024
 
Via Benzinga
News headline image
Sage Therapeutics Stock Eyes Best Day In 5 Years On Biogen’s Unsolicited Bid: Retail Piles In ↗
January 13, 2025
The two companies have collaborated since 2020 on the depression drug Zurzuvae, approved in 2023 by the FDA for treating postpartum depression. 
Via Stocktwits
News headline image
Biogen Bid For Sage Therapeutics Could Strengthen Neurology Strategy: Analysts ↗
January 13, 2025
Biogen proposes acquiring Sage Therapeutics for $7.22 per share, as analysts highlight the strategic value of Zurzuvae's success in postpartum depression. 
Via Benzinga
News headline image
Crude Oil Surges 3%; Abercrombie & Fitch Shares Plunge ↗
January 13, 2025
 
Via Benzinga
News headline image
Intra-Cellular Therapies, Standard BioTools, SI-BONE And Other Big Stocks Moving Higher On Monday ↗
January 13, 2025
 
Via Benzinga
News headline image
Why Is Depression-Focused Sage Therapeutics Stock Surging Higher On Monday? ↗
January 13, 2025
Sage Therapeutics reviews Biogen's $7.22 per share acquisition proposal amid ongoing restructuring and focus on Zurzuvae for postpartum depression. 
Via Benzinga
News headline image
Sage Therapeutics's Earnings: A Preview ↗
October 28, 2024
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
January 13, 2025
 
Via Benzinga
News headline image
Why Sage Therapeutics Shares Are Trading Higher By Over 34%; Here Are 20 Stocks Moving Premarket ↗
January 13, 2025
 
Via Benzinga
News headline image
Sage Therapeutics to Present 2025 Strategic Focus at 43rd Annual J.P. Morgan Healthcare Conference
January 12, 2025
From Sage Therapeutics
Via Business Wire
News headline image
Sage Therapeutics Confirms Receipt of Unsolicited Nonbinding Acquisition Proposal from Biogen
January 10, 2025
From Sage Therapeutics, Inc.
Via Business Wire
News headline image
Sage Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025
January 08, 2025
From Sage Therapeutics
Via Business Wire
News headline image
Sage Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference
November 26, 2024
From Sage Therapeutics, Inc.
Via Business Wire
News headline image
This Palo Alto Networks Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday ↗
November 21, 2024
 
Via Benzinga
News headline image
After Failed Alzheimer's Study, Sage Therapeutics' Dalzanemdor Flunks Another Study In Patients With Inherited Brain Disorder ↗
November 20, 2024
Sage Therapeutics ends dalzanemdor development after Phase 2 trials for Huntington's and Alzheimer's fail to meet primary endpoints. 
Via Benzinga
News headline image
Sage Therapeutics Announces Topline Results from the Phase 2 DIMENSION Study of Dalzanemdor (SAGE-718) in the Treatment of Cognitive Impairment Associated with Huntington’s Disease
November 20, 2024
From Sage Therapeutics, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
October 30, 2024
 
Via Benzinga
News headline image
Sage Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Pipeline and Business Updates
October 29, 2024
From Sage Therapeutics, Inc.
Via Business Wire
News headline image
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Sage Therapeutics, Inc. (SAGE)
October 25, 2024
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
Rosen Law Firm Urges Sage Therapeutics, Inc. (NASDAQ: SAGE) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
October 23, 2024
From Rosen Law Firm
Via Business Wire
News headline image
Faruqi & Faruqi Reminds Sage Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 28, 2024 - SAGE
October 23, 2024
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Methode Electronics, Starbucks, Endava, and Sage and Encourages Investors to Contact the Firm
October 22, 2024
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
SAGE THERAPEUTICS, INC. (NASDAQ: SAGE) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Sage Therapeutics, Inc. Investors of Upcoming Deadline
October 21, 2024
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
After Series Of Trial Setbacks, Sage Therapeutics To Lay Off One-Third Workforce ↗
October 17, 2024
Sage Therapeutics announces reorganization, including layoffs and pipeline changes, to support the launch of Zurzuvae. Focus shifts to Huntington's Disease trial after setbacks in essential tremor and... 
Via Benzinga
Topics Workforce
News headline image
Sage Therapeutics Announces Strategic Reorganization to Prioritize ZURZUVAE® Commercialization and Focus its Development Portfolio
October 17, 2024
From Sage Therapeutics, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap